The technologies and techniques developed for eye transplantation and nerve regeneration may have significant translational potential for other biomedical needs including: spinal cord injury, central nervous system regeneration, retinal cell and tissue transplantation, and other forms of organ and tissue transplantation.
Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.
To ensure effective cost mitigation, employers can’t wait for the market to adjust — they have to punch first.
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of development for other eye diseases. Alcon has been an active dealmaker, turning to M&A as a way to bolster its eye products portfolio and pipeline.
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
Orange County, California-based Glaukos announced that the approval indicates use of the device, along with cataract surgery, makes it the first micro-invasive glaucoma surgery in Japan.
Applications and video games could be the next best way to assess eye health. That's the approach Vizzario it taking.
Who accredits health plans for mental health parity compliance? Learn about the only organization that offers this program to ensure your members get equitable care.
InnFocus has raised funds to further develop its InnFocus MicroShunt glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma.